The “
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer” was published in
JITC July 15, 2021 as an update to SITC’s 2017 guidelines on bladder carcinoma. Immunotherapeutic options for the treatment of urothelial cancer have expanded substantially since the 2017 publication with approvals for checkpoint inhibitors in multiple advanced disease settings and emerging data on adjuvant approaches. SITC's urothelial expert panel generated updated and expanded evidence- and consensus-based recommendations on important aspects of immunotherapeutic treatment for urothelial cancer, including diagnostic testing, treatment planning, immune-related adverse events (irAEs), and patient quality of life (QOL) considerations to help clinicians navigate the evolving therapeutic landscape and ultimately improve outcomes for patients.
July 15, 2021